Results 41 to 50 of about 79,600 (335)
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
Therapeutic Advances in Medical Oncology, 2023 Numerous clinical trials investigating neoadjuvant immune checkpoint inhibitors (ICI) have been performed over the last 5 years. As the number of neoadjuvant trials increases, attention must be paid to identifying informative trial endpoints.Robert B. Cameron, Jacobi B. Hines, Valter Torri, Luca Porcu, Jessica Donington, Christine M. Bestvina, Everett Vokes, James M. Dolezal, Alessandra Esposito, Marina C. Garassino +9 moredoaj +1 more sourceAn Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics [PDF]
, 2018 For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types.A. Abeshouse, A. Ally, A. Antenucci, A. Arnaout, A. Berchuck, A. Bergeron, A. Bossler, A. Boussioutas, A. Breggia, A. Burnette, A. Chen, A. Clipca, A. Davis, A. De Rienzo, A. De Rose, A. Fehrenbach, A. Gillis, A. Gimenez-Roqueplo, A. Gopalan, A. Haddad, A. Hartmann, A. Jimeno, A. Kastl, A. Kendler, A. Kibel, A. Korkut, A. Longatto-Filho, A. Luna, A. Malykh, A. Mariamidze, A. Mes-Masson, A. Noss, A. Ochoa, A. Perin, A. Piché, A. Pickens, A. Rao, A. Sankarankuty, A. Secord, A. Sepulveda, A. Shabunin, A. Sharp, A. Sood, A. Spillane, A. Tam, A. Tischler, A. Tsao, A. Unterberg, A. Vicha, A. von Deimling, A.C. Berger, A.C. de Carvalho, A.D. Cherniack, A.D. Cherniack, A.E. Sloan, A.G. Robertson, A.H. Bryce, A.H. Perou, A.J. Kovatich, A.J. Kovatich, A.J. Lazar, A.J. Lazar, A.J. Mungall, A.K. Godwin, A.L. Carvalho, A.L. Guillermo, A.M. Angulo Gonzalez, A.M. Hegde, A.P. Hoyle, A.R. Metwalli, A.V. Lee, B. Bernard, B. Campos, B. Czerniak, B. Deyarmin, B. Drake, B. Esmaeli, B. Hermes, B. Hernandez, B. Kohl, B. Kumar, B. Pollo, B. Rabeno, B. Robinson, B. Singh, B. Tê, B. Van Tine, B. Wullich, B.D. Phu, B.E. Gross, B.M. Broom, B.P. O’, B.S. Taylor, B.Y. Karlan, C. Adebamowo, C. Andry, C. Behrens, C. Benz, C. Bifulco, C. Bradford, C. Brewer, C. Calatozzolo, C. Carter, C. Chen, C. Cibulskis, C. Fan, C. Farver, C. Feltmate, C. Goparaju, C. Guo, C. Herold-Mende, C. Hovens, C. Jungk, C. Kandoth, C. Larson, C. Logothetis, C. Mcpherson, C. Mirsaidi, C. Moran, C. Morrison, C. Moser, C. Sander, C. Scapulatempo-Neto, C. Schilero, C. Shelton, C. Shipman, C. Stoehr, C. Yau, C.A. Miller, C.C. Benz, C.C. Fronick, C.D. Jones, C.D. Shriver, C.D. Shriver, C.D. Vocke, C.H. Hagedorn, C.J. Creighton, C.K. Wong, C.M. Cebulla, C.M. Hutter, C.M. Perou, C.N. Landen, C.P. Raut, C.S. Shelley, C.W. Seder, D. Alvaro, D. Aziz, D. Beer, D. Bell, D. Bigner, D. Brooks, D. Chakravarty, D. Chesla, D. Crain, D. Cramer, D. Hoon, D. Huntsman, D. Lee, D. Mallery, D. Morton, D. Murawa, D. Muzny, D. Nagorney, D. O’, D. Raymond, D. Rice, D. Schadendorf, D. Tan, D. Tcaciuc, D. Tirapelli, D. Voet, D.A. Levine, D.A. Levine, D.A. Wheeler, D.I. Heiman, D.J. Brat, D.J. Van Den Berg, D.J. Weisenberger, D.M. Rassl, D.M. Shin, D.M. Wolf, D.N. Hayes, D.O. Vidal, D.T. Maglinte, E. Baudin, E. Campo, E. Castle, E. Chuah, E. Curley, E. Gaudio, E. Giné, E. Kebebew, E. Korpershoek, E. Lipp, E. Reznik, E. Shinbro, E. Swisher, E. Thompson, E. Zmuda, E.C. Zwarthoff, E.G. Van Meir, E.L. Appelbaum, E.M. Godwin, E.M. Mora Pinero, E.R. Duffy, E.R. Mardis, F. Beuschlein, F. Brimo, F. Carey, F. Cheng, F. Dimeco, F. Facciolo, F. Giuliante, F. Khuri, F. Meric-Bernstam, F. Moiseenko, F. Que, F. Saad, F. Sanchez-Vega, F. Valdivieso, F. Williams, F. Zhao, G. Barnett, G. Bubley, G. Carlos, G. Carpino, G. Finocchiaro, G. Getz, G. Gorincioi, G. Grazi, G. Long, G. Manikhas, G. Mann, G. Mckercher, G. Petersen, G. Saksena, G. Sauter, G. Setdikova, G. Sica, G. Thomas, G. Wolf, G.B. Mills, G.F. Gao, H. Al-Ahmadie, H. Colman, H. Dinh, H. Doddapaneni, H. Fan, H. Gabra, H. Gavin, H. Hai, H. Hai, H. Hibshoosh, H. Huland, H. Jianhong, H. Juhl, H. Kakavand, H. Liang, H. Noushmehr, H. Pass, H. Sekhon, H. Shen, H. Stoop, H. Taubert, H. Thai, H. Timmers, H. Yang, H. Zaren, H. Zhang, H. Zhang, H. Zhang, H.C.S. Silveira, H.G. Rosenthal, H.J. Sofia, H.K. Schmidt, I. Alexopoulou, I. Caraman, I. Chemencedji, I. de Bruijn, I. Felau, I. Forgie, I. Shmulevich, I. Stancul, I. Wistuba, I. Yang, J. Armenia, J. Bartlett, J. Bennett, J. Bondaruk, J. Bowen, J. Carlotti, J. Catto, J. Chabot, J. Cheville, J. Cho, J. Creaney, J. Dipersio, J. Drummond, J. Eckman, J. Engel, J. Eschbacher, J. Fujimoto, J. Fulop, J. Galbraith, J. Gao, J. Gardner, J. Gershenwald, J. Harr, J. Henderson, J. Hess, J. Hilty, J. Houck, J. Kim, J. Kocher, J. Lang, J. Liu, J. Liu, J. Luketich, J. Marks, J. Martin, J. Melamed, J. Miller, J. Moyer, J. Myers, J. Parfitt, J. Park, J. Paulauskis, J. Phillips, J. Powers, J. Roach, J. Santibanez, J. Shih, J. Simko, J. Slotta-Huspenina, J. Smith, J. Stretch, J. Thompson, J. Waldmann, J. Walker, J. Wang, J. Wang, J. Wilmott, J. Zhang, J. Zhenlin, J.(. Zhang, J.A. Ajani, J.A. Borgia, J.A. Copland, J.A. Demchok, J.A. Hooke, J.A. Martignetti, J.B. Elder, J.C. Zenklusen, J.D. Yang, J.E. Schein, J.H. Fregnani, J.I. Lee, J.J. Olson, J.L. Fantacone-Campbell, J.M. Chan, J.M. Gastier-Foster, J.M. Stuart, J.N. Weinstein, J.S. Barnholtz-Sloan, J.S. Dos Santos, J.S. Parker, J.T. Auman, J.V. Simons, K. Agnew, K. Ahn, K. Becker, K. Birsoy, K. Chang, K. Chung, K. Covington, K. Delman, K. Devine, K. Evason, K. Janssen, K. Junker, K. Kasaian, K. Kopp, K. Lau, K. Lee, K. Leinonen, K. Magliocca, K. Moore, K. Moxley, K. Mungall, K. Pacak, K. Rai, K. Roggin, K. Senecal, K. Shannon, K. Shimmel, K. Smith-McCune, K. Smolenski, K. Tse, K. Tucker, K.A. Hoadley, K.A. Hoadley, K.C. Sexton, K.E. van Kessel, K.J. Kang, K.M. Fong, K.M. Leraas, L. Cope, L. Cuppini, L. Danilova, L. Desjardins, L. Ding, L. Haydu, L. Jacobus, L. Jun, L. Konnor, L. Kvecher, L. Lacombe, L. Landrum, L. Lewis, L. Lolla, L. Looijenga, L. Mattei, L. Omberg, L. Omberg, L. Peterson, L. Ramondetta, L. Roberts, L. Rozek, L. Scarpace, L. Schoenfield, L. Wang, L. Wei, L. Wise, L. Xuan, L. Yang, L. Yiling, L. Zhang, L.A. Donehower, L.A. Fulton, L.A. Zach, L.E. Mose, L.M. Poisson, L.S. Schmidt, M. Albert, M. Aymerich, M. Bailey, M. Balasundaram, M. Behera, M. Bellair, M. Birrer, M. Borad, M. Carney, M. Cernat, M. Couce, M. Deqin, M. Dinkin, M. Dubina, M. Farnell, M. Fassnacht, M. Feldman, M. Gerken, M. Goodman, M. Graefen, M. Iacocca, M. Ittmann, M. Kasapi, M. Kendrick, M. Knudson, M. Ladanyi, M. Latour, M. Mannelli, M. Marino, M. Mayo, M. Mcgraw, M. Meyerson, M. Milhem, M. Miller, M. Moncrieff, M. Morgan, M. Muto, M. Nelson, M. Peto, M. Pirtac, M. Pool, M. Prados, M. Prince, M. Quinn, M. Quintero-Aguilo, M. Rivera, M. Ryan, M. Schiffman, M. Sherman, M. Sheth, M. Stanton, M. Stern, M. Synott, M. Tavobilov, M. Torbenson, M. Wang, M. Wiznerowicz, M. Yussanne, M.A. Marra, M.A. Rubin, M.C. Bragazzi, M.D. Mclellan, M.D. Wilkerson, M.G. Cordes, M.G. Nissan, M.G. Soloway, M.H. Abdel-Rahman, M.H. Kucherlapati, M.J. Liptay, M.L. Anderson, M.L. Ferguson, M.S. Bootwalla, M.S. Lawrence, M.S. Noble, N. Botnariuc, N. Chambwe, N. Corcoran, N. Dhalla, N. Gehlenborg, N. Giama, N. Girard, N. Hayward, N. Horowitz, N. Kwok-Shing, N. Schultz, N. Thiessen, N. Van Bang, N. Wentzensen, N.A. Pennell, N.C. Ramirez, N.D. Aredes, N.L. Lehman, N.P. Hung, N.V. Tien, O. Bathe, O. Mariani, O. Olabode, O. Paklina, O. Potapova, O. Voronina, P. Anur, P. Disaia, P. Drwiega, P. Glenn, P. Hansen, P. Hersey, P. Lin, P. Lohavanichbutr, P. Nair, P. Nguyen, P. Sipahimalani, P. Spellman, P. Swanson, P. Tamboli, P. Tennstedt, P. Troncoso, P. Wakely, P. Westervelt, P. Yena, P.A. Mieczkowski, P.A. Pinto, P.D. Castro, P.H. Lai, P.R. Carroll, P.R. Dottino, P.T. Hanh, P.W. Laird, Q. Sun, Q.T. Ostrom, R. Akbani, R. Berkowitz, R. Beroukhim, R. Bowlby, R. Bowman, R. Broaddus, R. Bueno, R. Carlsen, R. de Krijger, R. Dhanasekaran, R. Dhir, R. Duell, R. Ghossein, R. Glenn, R. Govindan, R. Holt, R. Kefford, R. Kemp, R. Korst, R. Kramer, R. Kundra, R. Lechan, R. Madan, R. Mandt, R. Mannel, R. Mclendon, R. Merola, R. Naresh, R. Penny, R. Pilarski, R. Postier, R. Saw, R. Scolyer, R. Sheridan, R. Sigmund, R. Simon, R. Singh, R. Smallridge, R. Steele, R. Stoehr, R. Tamakawa, R. Tarnuzzer, R. Thorp, R. Warnick, R. Worrell, R. Zuna, R.A. Gibbs, R.A. Moore, R.C. Rintoul, R.H. Thompson, R.J. Mural, R.K. Kelley, R.K. Wilson, R.M. Reis, R.S. Fulton, R.S. Kanchi, R.S. Kucherlapati, S. Balu, S. Baylin, S. Bell, S. Chevalier, S. Chudamani, S. Cottingham, S. Cuzzubbo, S. Doruc, S. Force, S. Frazer, S. Gilbert, S. Heath, S. Kalkanis, S. Kendall, S. Lee, S. Ling, S. Maithel, S. Mccall, S. Meier, S. Meng, S. Morris, S. Mura, S. Porten, S. Ramalingam, S. Reynolds, S. Roman-Roman, S. Sadeghi, S. Sifri, S. Signoretti, S. Singer, S. Somiari, S. Stepa, S. Tao, S. Vandenberg, S. Wach, S.B. Gabriel, S.E. Schumacher, S.J. Caesar-Johnson, S.J.M. Jones, S.L. Asa, S.M. Phillips, S.M. Staugaitis, S.N. Adebamowo, S.O. Sumer, S.R. Jefferys, T. Akeredolu, T. Bocklage, T. Bodenheimer, T. Broudy, T. Carey, T. Costello, T. Defreitas, T. Flotte, T. Giordano, T. Hinoue, T. Knijnenburg, T. Knutson, T. Ley, T. Lichtenberg, T. Mikkelsen, T. Naska, T. Owonikoko, T. Patel, T. Pihl, T. Schlomm, T. Shelton, T. Skelly, T. Smyrk, T. Thompson, T. Wang, T. Wong, T. Zelinka, T.A. Chan, T.M. Lichtenberg, U. Veluvolu, V. Cardinale, V. Chandan, V. Dhankani, V. Jakrot, V. Korchina, V. Lyadov, V. Reuter, V. Thorsson, V. Thorsson, W. Barrett, W. Eijckenboom, W. Hale, W. Kycler, W. Liu, W. Oosterhuis, W. Urba, W. Ye, W. Zhang, W. Zhou, W.E. Grizzle, W.G. Richards, W.J. Edenfield, W.K. Chatila, W.K. Rathmell, W.M. Linehan, X. Liu, X. Liu, X. Sastre, Y. Han, Y. Liu, Y. Shi, Y. Sun, Y. Tang, Y. Wan, Y. Wolinsky, Z. Wang, Z.J. Heins +740 morecore +2 more sourcesThe perils of surrogate endpoints [PDF]
European Heart Journal, 2015 Our goals in medicine are (i) to improve the quality of patients' lives, (ii) help them to live longer, and (iii) to do so at a reasonable cost. These are our true endpoints: health status, survival, and cost. It is thus entirely consistent with this point of view that these are the fundamental concepts that can be united in a formal cost–utility ...Weintraub, William S, Lüscher, Thomas F, Pocock, Stuart +2 moreopenaire +4 more sourcesBiomarkers and surrogate endpoints [PDF]
British Journal of Clinical Pharmacology, 2005 When David Beckham leaves the field towards the end of a match, the man who replaces him is a surrogate. and although I suspect that many footballers, if asked, would say that Surrogate is a town in Yorkshire, the word actually comes from the Latin word subrogare, to substitute.openaire +3 more sourcesExternal validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort
JHEP ReportsBackground & Aims: The goal of treatment in autoimmune hepatitis (AIH) is induction of remission to prevent the development of liver fibrosis, cirrhosis, and its related complications. Various definitions of treatment response and remission have been Lorenz Grossar, Sarah Raevens, Christophe Van Steenkiste, Isabelle Colle, Charlotte De Vloo, Hans Orlent, Jeoffrey Schouten, Marie Gallant, Annelien Van Driessche, Sander Lefere, Lindsey Devisscher, Anja Geerts, Hans Van Vlierberghe, Xavier Verhelst +13 moredoaj +1 more sourceDefining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria. [PDF]
PLoS ONE, 2017 Clinical trials in severe falciparum malaria require a large sample size to detect clinically meaningful differences in mortality. This means few interventions can be evaluated at any time. Using a validated surrogate endpoint for mortality would provide Atthanee Jeeyapant, Hugh W Kingston, Katherine Plewes, Richard J Maude, Josh Hanson, M Trent Herdman, Stije J Leopold, Thatsanun Ngernseng, Prakaykaew Charunwatthana, Nguyen Hoan Phu, Aniruddha Ghose, M Mahtab Uddin Hasan, Caterina I Fanello, Md Abul Faiz, Tran Tinh Hien, Nicholas P J Day, Nicholas J White, Arjen M Dondorp +17 moredoaj +1 more sourceClinical Implication of Targeting of Cancer Stem Cells [PDF]
, 2012 The existence of cancer stem cells (CSCs) is receiving increasing interest particularly due to its potential ability to enter clinical routine. Rapid advances in the CSC field have provided evidence for the development of more reliable anticancer ...Al-Hajj M, Bao S, Bardsley MR, Barlogie B, Bentzen SM, Bertout JA, Blazek ER, Bruns CJ, Brunsvig PF, C.J. Bruns, Cao X, Chen MS, Clayton S, Collins AT, Cortes J, Costello R, Dalerba P, Diehn M, Dou J, Dylla SJ, Eyler CE, Fischer S, Garvalov BK, Ghiaur G, Gibbs CP, Gilbert CA, H. Niess, Haferlach T, Hochhaus A, Hosen N, Huff CA, Hurwitz H, Jiang X, Jones RJ, Jones RJ, Jones RJ, Ju Z, K.-W. Jauch, Kanamori M, Kiladjian JJ, Klonisch T, Kojima T, Korpal M, L. Zhao, Li C, Liu G, Liu R, Liu S, Lonardo E, Mauro MJ, McDermott SP, Merante S, Mimeault M, Moserle L, O’Brien SG, Park CY, Phillips TM, Platet N, Q. Bao, Rasheed ZA, Reya T, Reya T, Richardson GD, Roeder I, Seidel S, Singh A, Singh SK, Strojnik T, Stupp R, Suh MR, Szotek PP, Tang C, Tang M, Todaro M, Tu LC, Vermeulen L, Wilson BJ, Wright MH, Xu N, Y. Zhao, Yu F, Zhao C, Zhou BB +82 morecore +1 more sourceEvaluating Candidate Principal Surrogate Endpoints
Biometrics, 2008 Summary Frangakis and Rubin (2002, Biometrics 58, 21–29) proposed a new definition of a surrogate endpoint (a “principal” surrogate) based on causal effects. We introduce an estimand for evaluating a principal surrogate, the causal effect predictiveness (CEP) surface, which quantifies how well causal treatment effects on the biomarker predict causal ...Gilbert, Peter B., Hudgens, Michael G.openaire +3 more sources
